BioGeneration Ventures closes BGV IV Fund at €105m

BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m.    


Investors into the oversubscribed BVG IV gathered existing actors — such as Bristol Myers Squibb, the European Investment Fund, and Schroder Adveq — as well as new partners embodied by KfW Capital and Industriens Pension. BGV is one of the largest VC funds in Europe focused on early investments in new biotechnology companies, and raised over €220m since 2006.

BioGeneration Ventures BV (BGV) is a VC specialist for seed and Series A financing. BGV operates as a joint venture with Forbion Capital Partners, providing a platform across early- to later-stage companies. According to BGV, the investment strategy for the BGV IV fund will follow the same path as other BGV funds.

Previous investment successes from BGV include Acerta Pharma, a company acquired by AstraZeneca for up to $7bn — and whose lead product Calquence has been approved and is marketed in the US —; and Staten Biotechnology, which signed a €430 million exclusive option deal with Novo Nordisk. Other companies in the current BGV portfolio include NorthSea Therapeutics, Azafaros, Varmx, and Confo Therapeutics.

According to Edward van Wezel, Managing Partner at BGV; “Over the last few years, BGV goal is translate promising science into transformational new medicines.”


Sign up for our newsletter!